Published in Drug Law Weekly, November 6th, 2007
The Endeavor Resolute stent will be launched in more than 50 countries in Europe, Asia, the Middle East and Africa by the end of 2007 - making Medtronic the first company to offer two internally developed drug-eluting stent options for the treatment of coronary artery disease, a condition affecting millions of people worldwide. The new stent is not approved in the United States.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.